期刊文献+

A strategy to produce monoclonal antibodies against gp96 by prime-boost regimen using endogenous protein and E.coli heterologously-expressed fragment 被引量:1

A strategy to produce monoclonal antibodies against gp96 by prime-boost regimen using endogenous protein and E.coli heterologously-expressed fragment
下载PDF
导出
摘要 Gp96, a member of HSP90 family, is a versatile molecular chaperone with various newly-discovered functions, for example to serve as a low affinity, high capacity calcium binding protein, a natural adjuvant for therapeutic cancer vaccines, a tumor rejection antigen, an immune regulator to pathological cell death. Its multi-functional and structural characteristics make it also an interesting target to develop antibody-based therapeutics. However, its low immunogenicity to mice, because of its high-sequence similarity among different species, is an obstacle to obtain valuable monoclonal antibodies (MAbs). This is a common problem for any low immunogenic proteins, whose sequences share close identity between mice and other species. Here, a new strategy of priming was employed by swine endogenous full-length gp96 and then boosting by E. coli-system heterologously expressed gp96 N-terminal fragment (N-355) to generate MAbs. Twelve different highly-specific MAbs against swine/human endogenous gp96 were successfully obtained. The binding activities of these MAbs were confirmed by enzyme-linked immunosorbent assay (ELISA), Western blot (WB), immunofluorescence and flow cytometry analysis. This provides some important reagents for further research and potential therapeutics. The methods employed can be used for MAb production of any sequence-highly-conserved proteins between mice and swine/human (or any other species). Gp96, a member of HSP90 family, is a versatile molecular chaperone with various newly-discovered functions, for example to serve as a low affinity, high capacity calcium binding protein, a natural adjuvant for therapeutic cancer vaccines, a tumor rejection antigen, an immune regulator to pathological cell death. Its multi-functional and structural characteristics make it also an interesting target to develop antibody-based therapeutics. However, its low immunogenicity to mice, because of its high-sequence similarity among different species, is an obstacle to obtain valuable monoclonal antibodies (MAbs). This is a common problem for any low immunogenic proteins, whose sequences share close identity between mice and other species. Here, a new strategy of priming was employed by swine endogenous full-length gp96 and then boosting by E. coli-system heterologously expressed gp96 N-terminal fragment (N-355) to generate MAbs. Twelve different highly-specific MAbs against swine/human endogenous gp96 were successfully obtained. The binding activities of these MAbs were confirmed by enzyme-linked immunosorbent assay (ELISA), Western blot (WB), immunofluorescence and flow cytometry analysis. This provides some important reagents for further research and potential therapeutics. The methods employed can be used for MAb production of any sequence-highly-conserved proteins between mice and swine/human (or any other species).
出处 《Journal of Central South University》 SCIE EI CAS 2011年第6期1857-1864,共8页 中南大学学报(英文版)
基金 Project(31030030) supported by the National Natural Science Foundation of China
关键词 单克隆抗体 钙结合蛋白 大肠杆菌表达 GP96 内源性 异源 酶联免疫吸附试验 流式细胞仪分析 monoclonal antibody priming-boost gp96 low immunogenic protein
  • 相关文献

参考文献1

二级参考文献40

  • 1Meng SD, Song J, RaoZ, TienP, Gao GF. Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides. J Immunol Methods 2002; 264:29-35.
  • 2Tanaka K, Kondoh N, Shuda M, Matsubara O, Imazeki N, Ryo A,Wakatsuki T, Hada A, Goseki N, Igafi T, Hatsuse K, Aihara T, Horiuchi S, Yamamoto N, Yamamoto M. Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocel.lular carcinomas. Biochim Biophys Acta 2001;1536:1-12.
  • 3Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15:948-963.
  • 4Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3:8-24.
  • 5Altmeyer A, Maki RG, Feldweg AM, Heike M, Protopopov VP,Masur SK, Srivastava PK. Tumor-specific cell surface expression of the-KDEL containing, endoplasmic reticular heat shock protein gp96. Int J Cancer 1996; 69:340-349.
  • 6vLHeike M, Frenzel C, Meier D, Galle PR. Expression of stress prorein gp96, a tumor rejection antigen, in human colorectal cancer.Int J Cancer 2000; 86:489-493.
  • 7Pal J, Somogyi C, Szmolenszky AA, Szekeres G, Sipos J, Hegedus G, Martzinovits I, Molnar J, Nemeth P. Immunohistochemical assessment and prognostic value of hepatitis B virus X protein in chronic hepatitis and primary hepatocellular carcinomas using antiHBxAg monoclonal antibody. Pathol Oncol Res 2001; 7:178-184.
  • 8Zhu M, London WT, Duan LX, Feitelson MA. The value of hepatitis B x antigen as a prognostic marker in the development of hepatocellular carcinoma. Int J Cancer 1993; 55: 571-576.
  • 9Wang WL, London WT, Feitelson MA. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991;51:4971-4977.
  • 10Mese H, Sasaki A, Nakayama S, Yoshioka N, Yoshihama Y Kishimoto K, Matsumura T. Prognostic significance of heat shock protein 27 (HSP27) in patients with oral squamous cell carcinoma.Oncol Rep 2002; 9:341-344.

共引文献21

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部